Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 8:43 p.m.

    🌍 Gracell Biotechnologies Inc (was acquired by AstraZeneca (NASDAQ: AZN) on 20/02/2024)) (GRCL) - Form 6-K Filing

    Filing Date: 2022-10-18

    Accepted: 2022-10-18 16:00:33

    Event Type: Clinical Trial Update

    Event Details:

    Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 12 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia. Clinical trial assessing allogeneic, HLA-matched, donor-derived allogenetic CAR-T therapy.

    💼 Business Developments:

    No specific business developments reported in this filing.

    📞 Contact Information:

    • Investor Contact: s Gracie Tong gracie.tong@gracellbio.com Stephanie Carrington stephanie.carringt
    • Media Contact: s Marvin Tang marvin.tang@gracellbio.com Kyle Evans kyle.evans@westwicke.com Inv
    • Email: marvin.tang@gracellbio.com

Search

News categories